March 8, 2004 - Norfolk, Va.- The results of one of the most anticipated clinical trials in cardiology will be released today by the American College of Cardiology (ACC).
Sentara Norfolk General Hospital was selected as one of the pilot sites for the progressive National Institutes of Health study called, SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Sudden cardiac death is a major public health problem, and is the leading cause of death in the United States. It affects more than 400,000 people each year. The two and a half year SCD-HeFT trial studied 2,500 congestive heart failure (CHF) patients identified to be at high risk for sudden cardiac death and examined whether implantable cardioverter-defibrillators (ICD) would improve survival compared to placebo in patients.
"The goal of the trial was to determine if the implantable defibrillator or ICD will prolong the lives of patients with heart failure," says John Herre, M.D., Cardiologist and principal Sentara SCD-HeFT researcher. "The information collected at Sentara Norfolk General Hospital has added significantly to the results of the trial."